Immunome Stock News & Updates
[WKN: A2QD9D | Symbol: IMNM]
Immunome (IMNM) in the Pivotal Point Check: Phase 3 Success with Varegacestat in Desmoid Tumors - Significant Improvement in Progression-Free Survival and 56% Response Rate Pave the Way for FDA Approval 2026!
The drug Varegacestat met the primary endpoint and significantly improved progression-free survival....
Immunome Inc. (IMNM): CEO Uses Capital Increase for a Private Investment of $1.16 Million
Immunome Inc. (IMNM) specializes in the development of targeted therapies to improve treatment outcomes...
- ‹
- 1
- ›